Prosecution Insights
Last updated: November 20, 2026
Application No. 18/686,702

METHOD FOR PRODUCING CYTIDINE-5'-DIPHOSPHATE COMPOUND

Non-Final OA §103
Filed
Mar 17, 2025
Priority
Aug 26, 2021 — WO PCT/JP2021/031429 +1 more
Examiner
MILLER, DALE R
Art Unit
1693
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kyowa Hakko Bio Co., Ltd.
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
461 granted / 737 resolved
+2.6% vs TC avg
Strong +18% interview lift
Without
With
+17.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
29 currently pending
Career history
772
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
46.9%
+6.9% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
14.5%
-25.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 737 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Pursuant to the preliminary amendment dated 11/29/205, claim 6 is cancelled. No claims are newly added. Claims 1-5 and 7-9 are pending in the instant application and are examined on the merits herein. Priority This application is a National Stage Application of PCT/JP2022/032235, filed on 8/26/2022. The instant application claims foreign priority to PCT/JP2021/031429 filed on 8/26/2021. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d). The certified copy has been filed in the instant application on 2/26/2024. Information Disclosure Statement The information disclosure statements (IDS) dated 5/24/2024, 12/31/2024, 2/4/2025, 5/15/2025, 6/2/2025, 9/4/2025, 9/16/2025, 11/24/2025, 1/16/2026, 2/11/2026, 3/13/2026, 4/2/2026, 4/23/2026, 5/26/2026 and 10/9/2026 comply with the provisions of 37 CFR 1.97, 1.98 and MPEP § 609, except where noted. Accordingly, the IDS documents have been placed in the application file and the information therein has been considered as to the merits. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-5 and 7-9 are rejected under 35 U.S.C. 103 as being unpatentable over Brown et al. (IN2012MUM2534, IDS), in view of Kaitaranta et al. (J. Chrom., 1981, PTO-892). Brown et al. discloses a process for isolating and purifying CDP-choline comprising: 1) absorbing CDP-choline onto a basic anion exchange resin, 2) washing the resin with water; 3) eluting the CDP-choline with a room temperature acidic solution, exemplified as a formic acid solution at 0.01-0.1 M and 4) concentrating the CDP-choline eluate using nanofiltration, at 25-30°C. (Example 2; p. 16; claim 6) Brown does not each that the elution solution comprises a carboxylic acid with more than one carbon. Kaitaranta et al. discloses a method for eluting CDP-choline from an anionic ion exchange resin using an acetic acid elution solution. Kaitaranta also teaches that the use of formic acid in the elution mixture is undesirable because of its irritant effect.(p. 329-330) It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the method of Brown to replace the formic acid with acetic acid, thereby arriving at the instant invention. One would be motivated to perform this replacement because Kaitaranta teaches that formic acid has an undesirable irritant effect. Applicant’s Examples herein have been fully considered but are not deemed persuasive as to the nonobviousness and/or unexpected results of the claimed invention over the prior art. While the instant specification provides working examples demonstrating the superior effectiveness of acetic or propionic acid, when compared to formic acid, as an elution solution, the evidence is not persuasive to overcome obviousness because the scope of the instant claims includes any organic acid with two or more carbons, at any concentration and at any temperature. In contrast, the evidence of unexpected results demonstrates superior performance with acetic or propionic acid, at 0.1-0.45 M and 20-60°C. Whether the unexpected results are the result of unexpectedly improved results or a property not taught by the prior art, the “objective evidence of nonobviousness must be commensurate in scope with the claims which the evidence is offered to support.” In other words, the showing of unexpected results must be reviewed to see if the results occur over the entire claimed range. In re Clemens, 622 F.2d 1029, 1036, 206 USPQ 289, 296 (CCPA 1980)(MPEP § 716.02(d)) Applicants’ showing of unexpected results are not commensurate in scope with that of the claimed invention. Accordingly, the instant claims are prima facie obvious over the teachings of the prior art. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DALE R MILLER whose telephone number is (571) 272-6146. The examiner can normally be reached on M-F 7:00 AM – 3:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached on (571) 270-5341. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center and the Private Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from Patent Center or Private PAIR. Status information for unpublished applications is available through Patent Center and Private PAIR to authorized users only. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /DALE R MILLER/Primary Examiner, Art Unit 1693
Read full office action

Prosecution Timeline

Mar 17, 2025
Application Filed
Dec 29, 2025
Response after Non-Final Action
Nov 13, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799146
COMPOSITIONS AND METHODS RELATED TO MODIFICATION AND DETECTION OF PSEUDOURIDINE AND 5-HYDROXYMETHYLCYTOSINE
3y 0m to grant Granted Nov 17, 2026
Patent 12797409
HEPARAN SULFATE MIMETICS TO IMPROVE GLUCOSE CLEARANCE
2y 11m to grant Granted Nov 17, 2026
Patent 12778972
NUTRITIONAL COMPOSITION COMPRISING HUMAN MILK OLIGOSACCHARIDES
3y 6m to grant Granted Nov 03, 2026
Patent 12779040
SELF-REPAIRING BIOMIMETIC LUBRICANTS AND METHODS OF MAKING AND USING SAME
3y 6m to grant Granted Nov 03, 2026
Patent 12780864
METHOD FOR PREPARING STACHYOSE
2y 4m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
80%
With Interview (+17.5%)
2y 7m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 737 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month